Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.
All the patients whom an investigator prescribes the first SUNITINIB MALATE(Sutent) should be registered.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| SUNITINIB MALATE | Patients taking Sutent. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| SUNITINIB MALATE | Drug | SUTENT capsule 12.5 mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. "The usual adult dosage for oral sunitinib is 50 mg once daily, 4 weeks on followed by 2 weeks off (Schedule 4/2). This comprises 1 treatment cycle, which may be repeated. The dosage may be decreased according to the patient's clinical condition." |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Treatment-Related Adverse Events | A treatment-related adverse event was any untoward medical occurrence attributed to sunitinib malate in a participant who received sunitinib malate. Relatedness to sunitinib malate was assessed by the investigator and sponsor (Pfizer Japan Inc.). | MAX 2 Years |
| Objective Response Rate | Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). The result was presented along with the corresponding exact 2-sided 95% confidence interval (CI). | MAX 2 Years |
| Measure | Description | Time Frame |
|---|---|---|
| Objective Response Rates by KIT Expression Status | Percentage of participants with objective response based assessment of CR or confirmed PR according to RECIST. Objective response rates by KIT expression status were calculated according to RECIST and were presented along with the corresponding exact 2-sided 95% CIs. | MAX 2 Years |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Treatment-Related Serious Adverse Events | A treatment-related adverse event was any untoward medical occurrence attributed to sunitinib malate in a participant who received sunitinib malate. A treatmen-trelated serious adverse event was a treatment-related adverse event resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; lifethreatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Relatedness to sunitinib malate was assessed by the investigator and sponsor (Pfizer Japan Inc.). |
Inclusion Criteria:
Patients need to be administered SUNITINIB MALATE(Sutent) in order to be enrolled in the surveillance.
Exclusion Criteria:
Patients not administered SUNITINIB MALATE(Sutent).
Not provided
Not provided
Not provided
The patients whom an investigator involving A6181175 prescribes the SUNITINIB MALATE(Sutent).
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
Not provided
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Sunitinib Malate | Usually, 50 mg of sunitinib malate was orally administered to adult participants once daily in repetitive cycles of 4 weeks on treatment followed by 2 weeks off according to Japanese package insert. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Sunitinib Malate | Usually, 50 mg of sunitinib malate was orally administered to adult participants once daily in repetitive cycles of 4 weeks on treatment followed by 2 weeks off according to Japanese package insert. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Customized | Number |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Participants With Treatment-Related Adverse Events | A treatment-related adverse event was any untoward medical occurrence attributed to sunitinib malate in a participant who received sunitinib malate. Relatedness to sunitinib malate was assessed by the investigator and sponsor (Pfizer Japan Inc.). | Safety analysis set comprised of participants who had met the inclusion criteria and had received sunitinib malate at least once. | Posted | Number | Participants | MAX 2 Years |
|
Not provided
The frequency of adverse events. The same event may appear as both an adverse event and a serious adverse event. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Sunitinib Malate | Usually, 50 mg of sunitinib malate was orally administered to adult participants once daily in repetitive cycles of 4 weeks on treatment followed by 2 weeks off according to Japanese package insert. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Pneumonia staphylococcal | Infections and infestations | MedDRA 18.0 | Non-systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Thrombocytopenia | Blood and lymphatic system disorders | MedDRA 18.0 | Non-systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Pfizer ClinicalTrials.gov Call Center | Pfizer, Inc. | 1-800-718-1021 | ClinicalTrials.gov_Inquiries@pfizer.com |
Not provided
| ID | Term |
|---|---|
| D046152 | Gastrointestinal Stromal Tumors |
| ID | Term |
|---|---|
| D009372 | Neoplasms, Connective Tissue |
| D018204 | Neoplasms, Connective and Soft Tissue |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077210 | Sunitinib |
| ID | Term |
|---|---|
| D011758 | Pyrroles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| Objective Response Rates by c-Kit Mutation Status |
Percentage of participants with objective response based assessment of CR or confirmed PR according to RECIST. Objective response rates by c-kit mutation status were calculated according to RECIST and were presented along with the corresponding exact 2-sided 95% CIs. |
| MAX 2 Years |
| Objective Response Rates by Platelet - Derived Growth Factor Receptor Alpha (PDGFRα) Mutation Status | Percentage of participants with objective response based assessment of CR or confirmed PR according to RECIST. Objective response rates by PDGFRα mutation status were calculated according to RECIST and were presented along with the corresponding exact 2-sided 95% CIs. | MAX 2 Years |
| Number of Participants With Treatment-Related Adverse Events in Elderly Population | A treatment-related adverse event was any untoward medical occurrence attributed to sunitinib malate in a participant who received sunitinib malate. Relatedness to sunitinib malate was assessed by the investigator and sponsor (Pfizer Japan Inc.). Elderly population was defined as the participants who aged 65 or older. | MAX 2 Years |
| Number of Participants With Treatment-Related Adverse Events Who Had Hepatic Impairment | A treatment-related adverse event was any untoward medical occurrence attributed to sunitinib malate in a participant who received sunitinib malate. Relatedness to sunitinib malate was assessed by the investigator and sponsor (Pfizer Japan Inc.). Hepatic impairment referred not to transient laboratory test value abnormalities, but to the events that were clinically noteworthy and required follow-up. | MAX 2 Years |
| Number of Participants With Treatment-Related Adverse Events Who Had Renal Impairment | A treatment-related adverse event was any untoward medical occurrence attributed to sunitinib malate in a participant who received sunitinib malate. Relatedness to sunitinib malate was assessed by the investigator and sponsor (Pfizer Japan Inc.). Renal impairment referred not to transient laboratory test value abnormalities, but to the events that were clinically noteworthy and required follow-up. | MAX 2 Years |
| Number of Participants With Treatment-Related Adverse Events Who Used Concomitant Cytochrome P450 3A4 (CYP3A4) Inhibitors | A treatment-related adverse event was any untoward medical occurrence attributed to sunitinib malate in a participant who received sunitinib malate. Relatedness to sunitinib malate was assessed by the investigator and sponsor (Pfizer Japan Inc.). A total of 38 drugs including tofisopam, bromocriptin mesilate, and fluvoxamine maleate were defined as CYP3A4 inhibitors. | MAX 2 Years |
| Number of Participants With Treatment-Related Adverse Events Who Were Under Long-Term Treatment | A treatment-related adverse event was any untoward medical occurrence attributed to sunitinib malate in a participant who received sunitinib malate. Relatedness to sunitinib malate was assessed by the investigator and sponsor (Pfizer Japan Inc.). The long-term treatment was defined as the treatment continued more than 24 weeks. | MAX 2 Years |
| Numbers of Participants With Treatment-Related Adverse Events Corresponded to Items for Priority Investigation | The following adverse events were defined as items for priority investigation : (1) lung disorder including interstitial pneumonia, (2) bone marrow depression including platelets decreased, white blood cell decreased, and anaemia, (3) haemorrhage including those due to tumor degeneration or shrinkage, (4) cardiac function disturbance including QT interval prolonged and left ventricular ejection fraction decreased, (5) dysfunction adrenal, (6) pancreatic dysfunction including lipase increased, (7) thyroid function decreased, (8) cutaneous symptoms (hand and foot syndrome), (9) serious infections, (10) rhabdomyolysis, myopathy, and (11) reversible posterior leukoencephalopathy syndrome (RPLS). Relatedness to sunitinib malate was assessed by the investigator and sponsor (Pfizer Japan Inc.). | MAX 2 Years |
| MAX 2 Years |
| Number of Participants With Treatment-Related Adverse Events Unexpected From Japanese Package Insert | A treatment-related adverse event was any untoward medical occurrence attributed to sunitinib malate in a participant who received sunitinib malate. Relatedness to sunitinib malate was assessed by the investigator and sponsor (Pfizer Japan Inc.). Expectedness of the adverse event was determined according to the Japanese package insert. Relatedness to sunitinib malate was assessed by the investigator and sponsor (Pfizer Japan Inc.). | MAX 2 Years |
| Number of Participants With Treatment-Related Adverse Events Grade 3 or Higher in Common Toxicity Criteria for Adverse Events (CTCAE) | A treatment-related adverse event was any untoward medical occurrence attributed to sunitinib malate in a participant who received sunitinib malate. Relatedness to sunitinib malate was assessed by the investigator and sponsor (Pfizer Japan Inc.). The severity for each adverse event was assessed according to CTCAE as follows: grade 3, severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, or disabling; grade 4, life-threatening consequences or urgent intervention indicated; grade 5, death related to adverse event. | MAX 2 Years |
| Participants |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Units | Counts |
|---|---|
| Participants |
|
|
| Primary | Objective Response Rate | Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). The result was presented along with the corresponding exact 2-sided 95% confidence interval (CI). | Efficacy analysis set comprised of participants in safety analysis set who had efficacy evaluation. | Posted | Number | 95% Confidence Interval | Percentage of participants | MAX 2 Years |
|
|
|
| Secondary | Objective Response Rates by KIT Expression Status | Percentage of participants with objective response based assessment of CR or confirmed PR according to RECIST. Objective response rates by KIT expression status were calculated according to RECIST and were presented along with the corresponding exact 2-sided 95% CIs. | Efficacy analysis set comprised of participants in safety analysis set who had efficacy evaluation. | Posted | Number | 95% Confidence Interval | Percentage of participants | MAX 2 Years |
|
|
|
| Secondary | Objective Response Rates by c-Kit Mutation Status | Percentage of participants with objective response based assessment of CR or confirmed PR according to RECIST. Objective response rates by c-kit mutation status were calculated according to RECIST and were presented along with the corresponding exact 2-sided 95% CIs. | Efficacy analysis set comprised of participants in safety analysis set who had efficacy evaluation. | Posted | Number | 95% Confidence Interval | Percentage of participants | MAX 2 Years |
|
|
|
| Secondary | Objective Response Rates by Platelet - Derived Growth Factor Receptor Alpha (PDGFRα) Mutation Status | Percentage of participants with objective response based assessment of CR or confirmed PR according to RECIST. Objective response rates by PDGFRα mutation status were calculated according to RECIST and were presented along with the corresponding exact 2-sided 95% CIs. | Efficacy analysis set comprised of participants in safety analysis set who had efficacy evaluation. | Posted | Number | 95% Confidence Interval | Percentage of participants | MAX 2 Years |
|
|
|
| Secondary | Number of Participants With Treatment-Related Adverse Events in Elderly Population | A treatment-related adverse event was any untoward medical occurrence attributed to sunitinib malate in a participant who received sunitinib malate. Relatedness to sunitinib malate was assessed by the investigator and sponsor (Pfizer Japan Inc.). Elderly population was defined as the participants who aged 65 or older. | Safety analysis set comprised of participants who had met the inclusion criteria and had received sunitinib malate at least once. | Posted | Number | Participants | MAX 2 Years |
|
|
|
| Secondary | Number of Participants With Treatment-Related Adverse Events Who Had Hepatic Impairment | A treatment-related adverse event was any untoward medical occurrence attributed to sunitinib malate in a participant who received sunitinib malate. Relatedness to sunitinib malate was assessed by the investigator and sponsor (Pfizer Japan Inc.). Hepatic impairment referred not to transient laboratory test value abnormalities, but to the events that were clinically noteworthy and required follow-up. | Safety analysis set comprised of participants who had met the inclusion criteria and had received sunitinib malate at least once. | Posted | Number | Participants | MAX 2 Years |
|
|
|
| Secondary | Number of Participants With Treatment-Related Adverse Events Who Had Renal Impairment | A treatment-related adverse event was any untoward medical occurrence attributed to sunitinib malate in a participant who received sunitinib malate. Relatedness to sunitinib malate was assessed by the investigator and sponsor (Pfizer Japan Inc.). Renal impairment referred not to transient laboratory test value abnormalities, but to the events that were clinically noteworthy and required follow-up. | Safety analysis set comprised of participants who had met the inclusion criteria and had received sunitinib malate at least once. | Posted | Number | Participants | MAX 2 Years |
|
|
|
| Secondary | Number of Participants With Treatment-Related Adverse Events Who Used Concomitant Cytochrome P450 3A4 (CYP3A4) Inhibitors | A treatment-related adverse event was any untoward medical occurrence attributed to sunitinib malate in a participant who received sunitinib malate. Relatedness to sunitinib malate was assessed by the investigator and sponsor (Pfizer Japan Inc.). A total of 38 drugs including tofisopam, bromocriptin mesilate, and fluvoxamine maleate were defined as CYP3A4 inhibitors. | Safety analysis set comprised of participants who had met the inclusion criteria and had received sunitinib malate at least once. | Posted | Number | Participants | MAX 2 Years |
|
|
|
| Secondary | Number of Participants With Treatment-Related Adverse Events Who Were Under Long-Term Treatment | A treatment-related adverse event was any untoward medical occurrence attributed to sunitinib malate in a participant who received sunitinib malate. Relatedness to sunitinib malate was assessed by the investigator and sponsor (Pfizer Japan Inc.). The long-term treatment was defined as the treatment continued more than 24 weeks. | Safety analysis set comprised of participants who had met the inclusion criteria and had received sunitinib malate at least once. | Posted | Number | Participants | MAX 2 Years |
|
|
|
| Secondary | Numbers of Participants With Treatment-Related Adverse Events Corresponded to Items for Priority Investigation | The following adverse events were defined as items for priority investigation : (1) lung disorder including interstitial pneumonia, (2) bone marrow depression including platelets decreased, white blood cell decreased, and anaemia, (3) haemorrhage including those due to tumor degeneration or shrinkage, (4) cardiac function disturbance including QT interval prolonged and left ventricular ejection fraction decreased, (5) dysfunction adrenal, (6) pancreatic dysfunction including lipase increased, (7) thyroid function decreased, (8) cutaneous symptoms (hand and foot syndrome), (9) serious infections, (10) rhabdomyolysis, myopathy, and (11) reversible posterior leukoencephalopathy syndrome (RPLS). Relatedness to sunitinib malate was assessed by the investigator and sponsor (Pfizer Japan Inc.). | Safety analysis set comprised of participants who had met the inclusion criteria and had received sunitinib malate at least once. | Posted | Number | Participants | MAX 2 Years |
|
|
|
| Other Pre-specified | Number of Participants With Treatment-Related Serious Adverse Events | A treatment-related adverse event was any untoward medical occurrence attributed to sunitinib malate in a participant who received sunitinib malate. A treatmen-trelated serious adverse event was a treatment-related adverse event resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; lifethreatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Relatedness to sunitinib malate was assessed by the investigator and sponsor (Pfizer Japan Inc.). | Safety analysis set comprised of participants who had met the inclusion criteria and had received sunitinib malate at least once. | Posted | Number | Participants | MAX 2 Years |
|
|
|
| Other Pre-specified | Number of Participants With Treatment-Related Adverse Events Unexpected From Japanese Package Insert | A treatment-related adverse event was any untoward medical occurrence attributed to sunitinib malate in a participant who received sunitinib malate. Relatedness to sunitinib malate was assessed by the investigator and sponsor (Pfizer Japan Inc.). Expectedness of the adverse event was determined according to the Japanese package insert. Relatedness to sunitinib malate was assessed by the investigator and sponsor (Pfizer Japan Inc.). | Safety analysis set comprised of participants who had met the inclusion criteria and had received sunitinib malate at least once. | Posted | Number | Participants | MAX 2 Years |
|
|
|
| Other Pre-specified | Number of Participants With Treatment-Related Adverse Events Grade 3 or Higher in Common Toxicity Criteria for Adverse Events (CTCAE) | A treatment-related adverse event was any untoward medical occurrence attributed to sunitinib malate in a participant who received sunitinib malate. Relatedness to sunitinib malate was assessed by the investigator and sponsor (Pfizer Japan Inc.). The severity for each adverse event was assessed according to CTCAE as follows: grade 3, severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, or disabling; grade 4, life-threatening consequences or urgent intervention indicated; grade 5, death related to adverse event. | Safety analysis set comprised of participants who had met the inclusion criteria and had received sunitinib malate at least once. | Posted | Number | Participants | MAX 2 Years |
|
|
|
| 259 |
| 472 |
| 429 |
| 472 |
| Device related sepsis | Infections and infestations | MedDRA 18.0 | Non-systematic Assessment |
|
| Cholangitis infective | Infections and infestations | MedDRA 18.0 | Non-systematic Assessment |
|
| Pyelonephritis acute | Infections and infestations | MedDRA 18.0 | Non-systematic Assessment |
|
| Neutropenic infection | Infections and infestations | MedDRA 18.0 | Non-systematic Assessment |
|
| Pneumonia bacterial | Infections and infestations | MedDRA 18.0 | Non-systematic Assessment |
|
| Gingivitis | Infections and infestations | MedDRA 18.0 | Non-systematic Assessment |
|
| Gingival abscess | Infections and infestations | MedDRA 18.0 | Non-systematic Assessment |
|
| Intervertebral discitis | Infections and infestations | MedDRA 18.0 | Non-systematic Assessment |
|
| Abscess | Infections and infestations | MedDRA 18.0 | Non-systematic Assessment |
|
| Nasopharyngitis | Infections and infestations | MedDRA 18.0 | Non-systematic Assessment |
|
| Abdominal abscess | Infections and infestations | MedDRA 18.0 | Non-systematic Assessment |
|
| Peritonitis | Infections and infestations | MedDRA 18.0 | Non-systematic Assessment |
|
| Gastric cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 18.0 | Non-systematic Assessment |
|
| Tumour necrosis | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 18.0 | Non-systematic Assessment |
|
| Gastrointestinal stromal tumour | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 18.0 | Non-systematic Assessment |
|
| Thrombotic microangiopathy | Blood and lymphatic system disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Haemorrhagic anaemia | Blood and lymphatic system disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Febrile neutropenia | Blood and lymphatic system disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Hypersensitivity | Immune system disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Hypopituitarism | Endocrine disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Hyperthyroidism | Endocrine disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Cachexia | Metabolism and nutrition disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Hyperamylasaemia | Metabolism and nutrition disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Hyperkalaemia | Metabolism and nutrition disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Hypercreatininaemia | Metabolism and nutrition disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Tumour lysis syndrome | Metabolism and nutrition disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Hypoglycaemia | Metabolism and nutrition disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Loss of consciousness | Nervous system disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Altered state of consciousness | Nervous system disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Syncope | Nervous system disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Ruptured cerebral aneurysm | Nervous system disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Dizziness | Nervous system disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Cardiac failure acute | Cardiac disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Bradycardia | Cardiac disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Cardiac disorder | Cardiac disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Cardio-respiratory arrest | Cardiac disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Sinus tachycardia | Cardiac disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Deep vein thrombosis | Vascular disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Hypotension | Vascular disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Aneurysm | Vascular disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Aneurysm ruptured | Vascular disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Interstitial lung disease | Respiratory, thoracic and mediastinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Laryngeal oedema | Respiratory, thoracic and mediastinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Pulmonary haemorrhage | Respiratory, thoracic and mediastinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Pneumonitis | Respiratory, thoracic and mediastinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Haemoptysis | Respiratory, thoracic and mediastinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Gastroduodenal haemorrhage | Gastrointestinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Gastrooesophageal reflux disease | Gastrointestinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Gastric perforation | Gastrointestinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Gastrointestinal obstruction | Gastrointestinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Gingival bleeding | Gastrointestinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Enterocolonic fistula | Gastrointestinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Small intestinal perforation | Gastrointestinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Gastrointestinal perforation | Gastrointestinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Dyspepsia | Gastrointestinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Upper gastrointestinal haemorrhage | Gastrointestinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Colitis | Gastrointestinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Large intestinal obstruction | Gastrointestinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Intestinal obstruction | Gastrointestinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Pancreatitis | Gastrointestinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Pancreatic enzyme abnormality | Gastrointestinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Jaundice | Hepatobiliary disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Jaundice cholestatic | Hepatobiliary disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Cholecystitis | Hepatobiliary disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Acute generalised exanthematous pustulosis | Skin and subcutaneous tissue disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Dermatitis bullous | Skin and subcutaneous tissue disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Dermatitis | Skin and subcutaneous tissue disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Myalgia | Musculoskeletal and connective tissue disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Pain in extremity | Musculoskeletal and connective tissue disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Flank pain | Musculoskeletal and connective tissue disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Nephrotic syndrome | Renal and urinary disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Renal failure | Renal and urinary disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Hydronephrosis | Renal and urinary disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Chronic kidney disease | Renal and urinary disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Vesical fistula | Renal and urinary disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Face oedema | General disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Pain | General disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Amylase increased | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| Haematocrit decreased | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| Gamma-glutamyltransferase increased | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| Blood albumin decreased | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| Blood lactate dehydrogenase increased | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| Blood uric acid increased | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| Blood urea increased | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| Glomerular filtration rate decreased | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| Protein urine present | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| Clavicle fracture | Injury, poisoning and procedural complications | MedDRA 18.0 | Non-systematic Assessment |
|
| Septic shock | Infections and infestations | MedDRA 18.0 | Non-systematic Assessment |
|
| Neoplasm progression | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 18.0 | Non-systematic Assessment |
|
| Hyperammonaemia | Metabolism and nutrition disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Hyponatraemia | Metabolism and nutrition disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Hypoaesthesia | Nervous system disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Cerebral haemorrhage | Nervous system disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Pneumonia aspiration | Respiratory, thoracic and mediastinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Melaena | Gastrointestinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Pancreatitis acute | Gastrointestinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Vomiting | Gastrointestinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Hepatic failure | Hepatobiliary disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Cholangitis acute | Hepatobiliary disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Cholangitis | Hepatobiliary disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Renal disorder | Renal and urinary disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Multi-organ failure | General disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Lipase increased | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| Lymphocyte count decreased | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| Electrocardiogram QT prolonged | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| Red blood cell count decreased | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| Bone marrow failure | Blood and lymphatic system disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Leukopenia | Blood and lymphatic system disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Hepatic encephalopathy | Nervous system disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Cardiac failure | Cardiac disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Dyspnea | Respiratory, thoracic and mediastinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Epistaxis | Respiratory, thoracic and mediastinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Stomatitis | Gastrointestinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Ascites | Gastrointestinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Abdominal pain | Gastrointestinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Liver disorder | Hepatobiliary disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Hyperbilirubinaemia | Hepatobiliary disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Rhabdomyolysis | Musculoskeletal and connective tissue disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Acute kidney injury | Renal and urinary disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Renal impairment | Renal and urinary disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Blood creatine phosphokinase increased | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| Sepsis | Infections and infestations | MedDRA 18.0 | Non-systematic Assessment |
|
| Pneumonia | Infections and infestations | MedDRA 18.0 | Non-systematic Assessment |
|
| Dehydration | Metabolism and nutrition disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Hypoalbuminaemia | Metabolism and nutrition disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Posterior reversible encephalopathy syndrome | Nervous system disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Pleural effusion | Respiratory, thoracic and mediastinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Ileus | Gastrointestinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Gastrointestinal haemorrhage | Gastrointestinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Intra-abdominal haemorrhage | Gastrointestinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Malaise | General disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Death | General disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Fatigue | General disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Blood creatinine increased | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| Blood bilirubin increased | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| Hyperuricaemia | Metabolism and nutrition disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Infection | Infections and infestations | MedDRA 18.0 | Non-systematic Assessment |
|
| Haemorrhage | Vascular disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Aspartate aminotransferase increased | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| Haemoglobin decreased | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| Hepatic function abnormal | Hepatobiliary disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Neutropenia | Blood and lymphatic system disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Hypothyroidism | Endocrine disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Thrombocytopenia | Blood and lymphatic system disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Hypertension | Vascular disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Disseminated intravascular coagulation | Blood and lymphatic system disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Palmar-plantar erythrodysaesthesia syndrome | Skin and subcutaneous tissue disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Decreased appetite | Metabolism and nutrition disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Pyrexia | General disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Anaemia | Blood and lymphatic system disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Neutrophil count decreased | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| Disease progression | General disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| White blood cell count decreased | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| Platelet count decreased | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| Nausea | Gastrointestinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Diarrhoea | Gastrointestinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Alanine aminotransferase increased | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| Blood alkaline phosphatase increased | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| Tumour haemorrhage | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 18.0 | Non-systematic Assessment |
|
| Neutropenia | Blood and lymphatic system disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Bone marrow failure | Blood and lymphatic system disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Leukopenia | Blood and lymphatic system disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Anaemia | Blood and lymphatic system disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Left ventricular dysfunction | Cardiac disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Hypothyroidism | Endocrine disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Hyperthyroidism | Endocrine disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Eyelid oedema | Eye disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Nausea | Gastrointestinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Gastrooesophageal reflux disease | Gastrointestinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Diarrhoea | Gastrointestinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Cheilitis | Gastrointestinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Stomatitis | Gastrointestinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Haemorrhoids | Gastrointestinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Dyspepsia | Gastrointestinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Abdominal pain upper | Gastrointestinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Glossitis | Gastrointestinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Ascites | Gastrointestinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Abdominal pain | Gastrointestinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Abdominal discomfort | Gastrointestinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Abdominal distension | Gastrointestinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Constipation | Gastrointestinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Vomiting | Gastrointestinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Proctalgia | Gastrointestinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Anal haemorrhage | Gastrointestinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Pancreatic enzyme abnormality | Gastrointestinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Performance status decreased | General disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Face oedema | General disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Chest pain | General disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Malaise | General disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Mucosal inflammation | General disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Pyrexia | General disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Fatigue | General disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Oedema | General disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Oedema peripheral | General disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Hepatic function abnormal | Hepatobiliary disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Liver disorder | Hepatobiliary disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Hyperbilirubinaemia | Hepatobiliary disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Periodontitis | Infections and infestations | MedDRA 18.0 | Non-systematic Assessment |
|
| Gingivitis | Infections and infestations | MedDRA 18.0 | Non-systematic Assessment |
|
| Nasopharyngitis | Infections and infestations | MedDRA 18.0 | Non-systematic Assessment |
|
| C-reactive protein increased | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| Gamma-glutamyltransferase increased | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| Aspartate aminotransferase increased | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| Amylase increased | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| Alanine aminotransferase increased | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| Haematocrit decreased | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| Haemoglobin decreased | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| Lipase increased | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| Lymphocyte count decreased | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| Ejection fraction decreased | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| Blood pressure increased | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| Platelet count decreased | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| Blood alkaline phosphatase increased | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| Blood albumin decreased | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| Blood creatinine increased | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| Blood creatine phosphokinase increased | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| Blood bilirubin increased | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| Blood thyroid stimulating hormone increased | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| Blood uric acid increased | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| Blood urea increased | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| Neutrophil count decreased | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| Red blood cell count decreased | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| Weight decreased | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| White blood cell count decreased | Investigations | MedDRA 18.0 | Non-systematic Assessment |
|
| Hyperamylasaemia | Metabolism and nutrition disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Hyperkalaemia | Metabolism and nutrition disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Hyperlipasaemia | Metabolism and nutrition disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Hyperuricaemia | Metabolism and nutrition disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Decreased appetite | Metabolism and nutrition disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Hypoalbuminaemia | Metabolism and nutrition disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Hypokalaemia | Metabolism and nutrition disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Hypocalcaemia | Metabolism and nutrition disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Hyponatraemia | Metabolism and nutrition disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Muscle spasms | Musculoskeletal and connective tissue disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Pain in extremity | Musculoskeletal and connective tissue disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Back pain | Musculoskeletal and connective tissue disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Hypoaesthesia | Nervous system disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Headache | Nervous system disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Dizziness | Nervous system disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Dysgeusia | Nervous system disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Insomnia | Psychiatric disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Renal impairment | Renal and urinary disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Proteinuria | Renal and urinary disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Cough | Respiratory, thoracic and mediastinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Pleural effusion | Respiratory, thoracic and mediastinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Upper respiratory tract inflammation | Respiratory, thoracic and mediastinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Dysphonia | Respiratory, thoracic and mediastinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Epistaxis | Respiratory, thoracic and mediastinal disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Pruritus | Skin and subcutaneous tissue disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Yellow skin | Skin and subcutaneous tissue disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Erythema | Skin and subcutaneous tissue disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Palmar-plantar erythrodysaesthesia syndrome | Skin and subcutaneous tissue disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Pigmentation disorder | Skin and subcutaneous tissue disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Alopecia | Skin and subcutaneous tissue disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Rash | Skin and subcutaneous tissue disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Haemorrhage subcutaneous | Skin and subcutaneous tissue disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Dermatitis | Skin and subcutaneous tissue disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Dry skin | Skin and subcutaneous tissue disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Skin disorder | Skin and subcutaneous tissue disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Skin discolouration | Skin and subcutaneous tissue disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Hypertension | Vascular disorders | MedDRA 18.0 | Non-systematic Assessment |
|
| Haemorrhage | Vascular disorders | MedDRA 18.0 | Non-systematic Assessment |
|
Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
| D005770 | Gastrointestinal Neoplasms |
| D004067 | Digestive System Neoplasms |
| D004066 | Digestive System Diseases |
| D005767 | Gastrointestinal Diseases |
| D007211 |
| Indoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| Title | Measurements |
|---|---|
|
| Cardiac function disturbance |
|
| Dysfunction adrenal |
|
| Pancreatic dysfunction |
|
| Thyroid function decreased |
|
| Cutaneous symptoms (hand and foot syndrome) |
|
| Serious infections |
|
| Rhabdomyolysis, myopathy |
|
| RPLS |
|